# Systemic anti-cancer therapy for advanced non-small-cell lung cancer

## Squamous non-small cell lung cancer, NTRK fusion positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) (only if urgent clinical intervention is needed) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), the next recommended treatment option is docetaxel.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment with docetaxel, recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), the next recommended treatment option is platinum doublet chemotherapy.

For people who have disease progression after platinum doublet chemotherapy, docetaxel is the next recommended treatment option.

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment with docetaxel, recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).